Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Anti GM-CSF Antibody Pipeline Insight Report, 2018 Edition - ResearchAndMarkets.com

Research and Markets
Posted on: 19 Dec 18

The "Anti GM-CSF Antibody -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Anti GM-CSF Antibody - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti GM-CSF Antibody development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for Anti GM-CSF Antibody - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Anti GM-CSF Antibody pipeline products by developmental stage, product type, molecule type, and administration route.

Key Topics Covered:

1. Report Introduction

2. Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products

4. Comparative Analysis

5. Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • KaloBios Pharmaceuticals
  • Takeda Pharmaceuticals
  • Zenyth Therapeutics
  • GlaxoSmithKline
  • Amgen

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/7p8htl/anti_gmcsf?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181219005731/en/

Business Wire
www.businesswire.com

Last updated on: 19/12/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.